Skip to main content
SpringerLink
Log in
Book cover

Inflammation and Cancer pp 1–23Cite as

The Role of Inflammation in Lung Cancer

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 816))

Abstract

Lung cancer remains a serious public health problem and is the first cause of cancer death worldwide, and the overall 5-year survival rate for all stages is 14–17 % for Non-small-cell lung cancer and 6 % for small-cell lung cancer. Clinical and epidemiologic studies have suggested a strong association among chronic infection, inflammation, and cancer. Immune system plays a critical role in maintaining tissue homeostasis, cell turnover, tissue remodeling, and preventing infection and cell transformation. The inflammatory component in the development of the neoplasm includes a diverse leukocyte population; these components are considered inflammatory tumor key factors promoting tumor progression due to its ability to release a variety of cytokines, chemokines, and cytotoxic mediators such as reactive oxygen species (ROS), metalloproteinases, interleukins, and interferons. Cancer-related inflammation affects many aspects of malignancy, including the proliferation and survival of malignant cells, angiogenesis, tumor metastasis, and tumor response to chemotherapeutic drugs and hormones. Moreover, epidemiologic studies and meta-analysis have shown that prolonged use of non-steroid anti-inflammatory (NSAID) drugs reduces the risk of several solid tumor including lung cancer. Strong lines of evidence suggest that the chemopreventive properties of chronic NSAID administration are based on their COX-inhibitory activity. However, the prevention is a much better and more economical way to fight against cancer than treating an already advanced and often incurable disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72(11):1605–1621. doi:10.1016/j.bcp.2006.06.029

    CAS  PubMed  Google Scholar 

  • Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2):425–430. doi:10.1158/1078-0432.CCR-08-0149

    CAS  PubMed  Google Scholar 

  • Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—A review of the literature. Oncologist 12(2):201–210. doi:10.1634/theoncologist.12-2-201

    CAS  PubMed  Google Scholar 

  • Asselin-Paturel C, Megherat S, Vergnon I, Echchakir H, Dorothee G, Blesson S, Gay F, Mami-Chouaib F, Chouaib S (2001) Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Cancer 91(1):113–122

    CAS  PubMed  Google Scholar 

  • Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28(1):12–24. doi:10.1165/rcmb.2002-0166TR

    CAS  PubMed  Google Scholar 

  • Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2(12):384–396. doi:10.5306/wjco.v2.i12.384

    PubMed Central  PubMed  Google Scholar 

  • Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251–6266. doi:10.1200/JCO.2009.23.5622

    CAS  PubMed Central  PubMed  Google Scholar 

  • Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0

    CAS  PubMed  Google Scholar 

  • Ballaz S, Mulshine JL (2003) The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 5(1):46–62. doi:10.3816/CLC.2003.n.021

    CAS  PubMed  Google Scholar 

  • Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RA (2001) Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int 25(5):411–420. doi:10.1006/cbir.2000.0647

    CAS  PubMed  Google Scholar 

  • Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16(1):38–52. doi:10.1016/j.semcancer.2005.07.006

    CAS  PubMed  Google Scholar 

  • Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, Roth M (1998) Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19(4):606–612. doi:10.1165/ajrcmb.19.4.3247

    CAS  PubMed  Google Scholar 

  • Borczuk AC, Papanikolaou N, Toonkel RL, Sole M, Gorenstein LA, Ginsburg ME, Sonett JR, Friedman RA, Powell CA (2008) Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 27(4):557–564. doi:10.1038/sj.onc.1210662

    CAS  PubMed Central  PubMed  Google Scholar 

  • Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Holscher AH, Danenberg KD, Danenberg PV (2002) Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 235(3):440–443

    PubMed Central  PubMed  Google Scholar 

  • Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thoracic Oncol: Official Pub Int Assoc Study Lung Cancer 6(4):824–833. doi:10.1097/JTO.0b013e3182037b76

    Google Scholar 

  • Brody JS, Spira A (2006) State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorc Soc 3(6):535–537. doi:10.1513/pats.200603-089MS

  • Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85(7):574–578

    CAS  PubMed  Google Scholar 

  • Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, Mortara L, Albini A, Noonan DM (2013) The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15(2):133–142

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chang KT, Huang CY, Tsai CM, Chiu CH, Lok YY (2005) Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. Am J Physiol Lung Cell Mol Physiol 289(3):L438–L445. doi:10.1152/ajplung.00033.2005

    CAS  PubMed  Google Scholar 

  • Chen W, Li Z, Bai L, Lin Y (2011) NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci: J Virtual Libr 16:1172–1185

    CAS  Google Scholar 

  • Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G, Medeiros R (2006) CXCL12-3’ A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol Immunother 55(6):639–643. doi:10.1007/s00262-005-0062-1

    PubMed  Google Scholar 

  • Cohen S (1965) The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 12(3):394–407

    CAS  PubMed  Google Scholar 

  • Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. doi:10.1038/nature01322

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507. doi:10.1016/S1470-2045(09)70035-X

    CAS  PubMed  Google Scholar 

  • Dalwadi H, Krysan K, Heuze-Vourc’h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S (2005) Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11(21):7674–7682. doi:10.1158/1078-0432.CCR-05-1205

    CAS  PubMed  Google Scholar 

  • de Mello RA, Marques DS, Medeiros R, Araujo AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2(11):367–376. doi:10.5306/wjco.v2.i11.367

    PubMed Central  PubMed  Google Scholar 

  • de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37. doi:10.1038/nrc1782

    PubMed  Google Scholar 

  • De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5(3):649–652

    PubMed  Google Scholar 

  • De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117(2):365–373

    PubMed  Google Scholar 

  • Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34. doi:10.1007/s10555-006-7886-9

    CAS  PubMed  Google Scholar 

  • Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT (2003) Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37:138–162

    CAS  PubMed  Google Scholar 

  • Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5(1):67–68

    CAS  PubMed  Google Scholar 

  • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998. doi:10.1038/ni1102-991

    CAS  PubMed  Google Scholar 

  • Duperron C, Castonguay A (1997) Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18(5):1001–1006

    CAS  PubMed  Google Scholar 

  • Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64(3):275–290

    CAS  PubMed  Google Scholar 

  • Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781. doi:10.1016/j.ejca.2009.12.014

    CAS  PubMed  Google Scholar 

  • Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10(8):554–567. doi:10.1038/nri2808

    CAS  PubMed  Google Scholar 

  • Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362

    CAS  PubMed  Google Scholar 

  • Gomes M, Coelho A, Araújo A, Catarino R, Medeiros R (2011) 1137 POSTER Is MMP-9 Q279R a possible marker of prognostic in non small cell lung cancer? Eur J Cancer (Oxford 1990) 47:S134–S135

    Google Scholar 

  • Gomes M, Coelho A, Araujo A, Teixeira AL, Catarino R, Medeiros R (2012) Influence of functional genetic polymorphism (−590C/T) in non-small cell lung cancer (NSCLC) development: the paradoxal role of IL-4. Gene 504(1):111–115. doi:10.1016/j.gene.2012.05.008

    CAS  PubMed  Google Scholar 

  • Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A (2012) Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12:121. doi:10.1186/1471-2407-12-121

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71(7):2411–2416. doi:10.1158/0008-5472.CAN-10-2583

    CAS  PubMed  Google Scholar 

  • Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1(1):11–21. doi:10.1038/35094017

    CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013

    CAS  PubMed  Google Scholar 

  • Harris RE, Beebe-Donk J, Alshafie GA (2007) Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 3(5):328–334

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M, Ueyama Y (2000) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11(7):815–819

    CAS  PubMed  Google Scholar 

  • Haynes A, Shaik MS, Chatterjee A, Singh M (2003) Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res 20(9):1485–1495

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355(9202):479–485. doi:10.1016/S0140-6736(00)82038-3

    CAS  PubMed  Google Scholar 

  • Hu Z, Huo X, Lu D, Qian J, Zhou J, Chen Y, Xu L, Ma H, Zhu J, Wei Q, Shen H (2005) Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 11(15):5433–5439. doi:10.1158/1078-0432.CCR-05-0311

    CAS  PubMed  Google Scholar 

  • Ishihara K, Hirano T (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13(4-5):357–368

    Google Scholar 

  • Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60(1):184–190

    CAS  PubMed  Google Scholar 

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107

    PubMed  Google Scholar 

  • Jumper C, Cobos E, Lox C (2004) Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 98(2):173–177

    PubMed  Google Scholar 

  • Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431–436. doi:10.1038/nature04870

    CAS  PubMed  Google Scholar 

  • Karin M (2008) The IkappaB kinase—a bridge between inflammation and cancer. Cell Res 18(3):334–342. doi:10.1038/cr.2008.30

    CAS  PubMed  Google Scholar 

  • Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67. doi:10.1016/j.cell.2010.03.015

    CAS  PubMed Central  PubMed  Google Scholar 

  • Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H (2007a) Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67(7):3475–3482. doi:10.1158/0008-5472.CAN-06-3941

    CAS  PubMed  Google Scholar 

  • Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H (2007b) Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28(1):163–173. doi:10.1093/carcin/bgl145

    CAS  PubMed  Google Scholar 

  • Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7(4):861–867

    CAS  PubMed  Google Scholar 

  • Koc M, Ediger D, Budak F, Karadag M, Oral HB, Uzaslan E, Ege E, Gozu RO (2006) Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 92(2):149–154

    CAS  PubMed  Google Scholar 

  • Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H (1993) Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53(9):1982–1985

    CAS  PubMed  Google Scholar 

  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703. doi:10.1056/NEJMoa1006448

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108. doi:10.1182/blood-2005-10-4160

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lee JM, Mao JT, Krysan K, Dubinett SM (2007) Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 3(2):149–153. doi:10.2217/14796694.3.2.149

    CAS  PubMed  Google Scholar 

  • Li F, Liu Y, Chen H, Liao D, Shen Y, Xu F, Wang J (2011) EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res 30:27. doi:10.1186/1756-9966-30-27

    PubMed Central  PubMed  Google Scholar 

  • Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J (2013) Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 8(1):e52093. doi:10.1371/journal.pone.0052093

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lin EY, Pollard JW (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90(11):2053–2058. doi:10.1038/sj.bjc.6601705

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175–1183. doi:10.1172/JCI31537

    CAS  PubMed Central  PubMed  Google Scholar 

  • Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962–972. doi:10.1016/S1470-2045(08)70206-7

    CAS  PubMed  Google Scholar 

  • Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y (2012) Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 7(2):e31251. doi:10.1371/journal.pone.0031251

    CAS  PubMed Central  PubMed  Google Scholar 

  • Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Urushihara M, Huang CL (2007) Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58(3):384–391. doi:10.1016/j.lungcan.2007.07.005

    PubMed  Google Scholar 

  • Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Molecular cancer research : MCR 4(4):221–233. doi:10.1158/1541-7786.MCR-05-0261

    PubMed  Google Scholar 

  • Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6(3):297–305. doi:10.1016/j.ccr.2004.08.012

    CAS  PubMed  Google Scholar 

  • Luo X, Ding Q, Wang M, Li Z, Mao K, Sun B, Pan Y, Wang Z, Zang YQ, Chen Y (2010) In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. PLoS One 5(4):e10149. doi:10.1371/journal.pone.0010149

    PubMed Central  PubMed  Google Scholar 

  • Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi:10.1038/nature07205

    CAS  PubMed  Google Scholar 

  • Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677–686. doi:10.1016/j.it.2004.09.015

    CAS  PubMed  Google Scholar 

  • Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555

    CAS  PubMed  Google Scholar 

  • Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM (2005) Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7(1):30–39. doi:10.3816/CLC.2005.n.019

    CAS  PubMed  Google Scholar 

  • Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D (2011) Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4(7):984–993. doi:10.1158/1940-6207.CAPR-11-0078

    CAS  Google Scholar 

  • Martey CA, Pollock SJ, Turner CK, O’Reilly KM, Baglole CJ, Phipps RP, Sime PJ (2004) Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 287(5):L981–L991. doi:10.1152/ajplung.00239.2003

    CAS  PubMed  Google Scholar 

  • Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384–1390. doi:10.1158/1078-0432.CCR-09-0788

    CAS  PubMed  Google Scholar 

  • Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90(12):2312–2316. doi:10.1038/sj.bjc.6601814

    CAS  PubMed Central  PubMed  Google Scholar 

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc Mayo Clin 83(5):584–594. doi:10.4065/83.5.584

    Google Scholar 

  • Montuenga LM, Pio R (2007) Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30(4):608–610. doi:10.1183/09031936.00091707

    CAS  PubMed  Google Scholar 

  • Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG (2002) RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 8(12):3803–3812

    CAS  PubMed  Google Scholar 

  • Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7(2):285–289

    CAS  PubMed  Google Scholar 

  • Nogueira A, Assis J, Catarino R, Medeiros R (2013) DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. Pharmacogenomics 14(6):689–700. doi:10.2217/pgs.13.48

    CAS  PubMed  Google Scholar 

  • O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thoracic Oncol: Off Pub Int Assoc Study Lung Cancer 5(12):2024–2036

    Google Scholar 

  • Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296(5574):1883–1886. doi:10.1126/science.1071420

    CAS  PubMed  Google Scholar 

  • Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM (2007) Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 7(10):1405–1421. doi:10.1586/14737140.7.10.1405

    CAS  PubMed  Google Scholar 

  • Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 22(5):607–613. doi:10.1097/MEG.0b013e3283352cbb

    CAS  PubMed  Google Scholar 

  • Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE, Harris CC (2011) Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Nat Cancer Inst 103(14):1112–1122. doi:10.1093/jnci/djr216

  • Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS (2005) Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4(9):1399–1408. doi:10.1158/1535-7163.MCT-05-0082

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ribeiro R, Araujo A, Lopes C, Medeiros R (2007) Immunoinflammatory mechanisms in lung cancer development: is leptin a mediator? J Thoracic Oncol: Off Pub Int Assoc Study Lung Cancer 2(2):105–108

    Google Scholar 

  • Rioux N, Castonguay A (1998) Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58(23):5354–5360

    CAS  PubMed  Google Scholar 

  • Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297. doi:10.1200/JCO.2009.23.5556

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schottenfeld D, Beebe-Dimmer J (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56(2):69–83

    PubMed  Google Scholar 

  • Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E (2008) Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44(12):1093–1099. doi:10.1016/j.oraloncology.2008.02.012

    CAS  PubMed  Google Scholar 

  • Setia S, Sanyal SN (2012) Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis. Pharmacol Rep: PR 64(3):615–624

    CAS  PubMed  Google Scholar 

  • Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, Lin LY (2005) The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50(3):291–297. doi:10.1016/j.lungcan.2005.07.007

    PubMed  Google Scholar 

  • Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717–727. doi:10.1016/j.ejca.2006.01.003

    CAS  PubMed  Google Scholar 

  • Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821. doi:10.1038/nrc1208

    CAS  PubMed  Google Scholar 

  • Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138

    PubMed  Google Scholar 

  • Smith CJ, Perfetti TA, King JA (2006) Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhalation Toxicol 18(9):667–677. doi:10.1080/08958370600742821

  • Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293. doi:10.1111/j.0105-2896.2004.00199.x

    CAS  PubMed  Google Scholar 

  • Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc 13(3):331–339

    CAS  Google Scholar 

  • Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS (2011) Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 17(16):5247–5256. doi:10.1158/1078-0432.CCR-10-2805

    CAS  PubMed  Google Scholar 

  • Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T (2005) Interleukin-4 in patients with prostate cancer. Anticancer Res 25(6C):4595–4598

    PubMed  Google Scholar 

  • Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 4:15. doi:10.3389/fphar.2013.00015

    PubMed Central  PubMed  Google Scholar 

  • Teixeira AL, Araujo A, Coelho A, Ribeiro R, Gomes M, Pereira C, Medeiros R (2011) Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J Cancer Res Clin Oncol 137(3):435–439. doi:10.1007/s00432-010-0896-6

    CAS  PubMed  Google Scholar 

  • Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822

    CAS  PubMed  Google Scholar 

  • Toi M, Bicknell R, Harris AL (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 52(2):275–279

    CAS  PubMed  Google Scholar 

  • Tsai CC, Chen CC, Lin CC, Chen CH, Lin TS, Shieh TY (1999) Interleukin-1 beta in oral submucous fibrosis, verrucous hyperplasia and squamous cell carcinoma tissues. Kaohsiung J Med Sci 15(9):513–519

    CAS  PubMed  Google Scholar 

  • Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K (2013) Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes 6(1):139. doi:10.1186/1756-0500-6-139

    CAS  PubMed Central  PubMed  Google Scholar 

  • Vaish V, Sanyal SN (2011) Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer. Pharmacol Rep: PR 63(5):1210–1221

    CAS  PubMed  Google Scholar 

  • Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P (2006) Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211(6–8):487–501. doi:10.1016/j.imbio.2006.06.002

    PubMed  Google Scholar 

  • Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157–166. doi:10.1002/ijc.10329

    CAS  PubMed  Google Scholar 

  • Wang HW, Joyce JA (2010) Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 9(24):4824–4835

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, Chen CY, Shieh SH, Lee H (2012) Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One 7(7):e39525. doi:10.1371/journal.pone.0039525

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7(9):493–507. doi:10.1038/nrclinonc.2010.97

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wu K, House L, Liu W, Cho WC (2012) Personalized targeted therapy for lung cancer. Int J Mol Sci 13(9):11471–11496. doi:10.3390/ijms130911471

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, Li CY (2006) Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 66(24):11565–11570. doi:10.1158/0008-5472.CAN-06-2540

    CAS  PubMed  Google Scholar 

  • Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T (1995) Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71(5):1095–1098

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397–10402. doi:10.1073/pnas.0604008103

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007) Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13(11):1747–1751

    CAS  PubMed  Google Scholar 

  • Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632. doi:10.1183/09031936.00129306

    CAS  PubMed  Google Scholar 

  • Zhan P, Qian Q, Yu LK (2013) Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thoracic Dis 5(1):40–47. doi:10.3978/j.issn.2072-1439.2013.01.02

    Google Scholar 

  • Zucker S, Lysik RM, Malik M, Bauer BA, Caamano J, Klein-Szanto AJ (1992) Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis. Int J Cancer 52(3):366–371

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Grupo de Oncologia Molecular—CI, Edifício Laboratórios, 4º piso Rua Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal

    Mónica Gomes, Ana Luísa Teixeira, Ana Coelho & Rui Medeiros

  2. ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal

    Mónica Gomes, Ana Luísa Teixeira & Rui Medeiros

  3. Faculty of Medicine of University of Porto, Porto, Portugal

    Ana Coelho

  4. LPCC Research Department-Portuguese League Against Cancer (NRNorte), Porto, Portugal

    Mónica Gomes, Ana Luísa Teixeira, Ana Coelho & Rui Medeiros

  5. CEBIMED, Health Sciences Faculty, Fernando Pessoa, University of Porto, Porto, Portugal

    Rui Medeiros

  6. Chief of the Medical Oncology Service of Centro Hospitalar do Porto, Porto, Portugal

    António Araújo

  7. Chief of the Medical Oncology Service of Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal

    António Araújo

  8. Instituto de Ciências Biomédicas de Abel Salazar, Porto, Portugal

    António Araújo

Authors
  1. Mónica Gomes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Luísa Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Coelho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. António Araújo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mónica Gomes .

Editor information

Editors and Affiliations

  1. Dept of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Bharat B. Aggarwal

  2. Dept of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Bokyung Sung

  3. Dep Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Subash Chandra Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Basel

About this chapter

Cite this chapter

Gomes, M., Teixeira, A.L., Coelho, A., Araújo, A., Medeiros, R. (2014). The Role of Inflammation in Lung Cancer. In: Aggarwal, B., Sung, B., Gupta, S. (eds) Inflammation and Cancer. Advances in Experimental Medicine and Biology, vol 816. Springer, Basel. https://doi.org/10.1007/978-3-0348-0837-8_1

Download citation

Publish with us

Policies and ethics

Search

Navigation